Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04 2022 - 7:30AM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President
and Chief Executive Officer, will present a corporate overview and
update at the 40th Annual J.P. Morgan Healthcare Conference on
Tuesday, January 11, 2022, at 5:15 p.m. ET (2:15 p.m. PT).
A live webcast of the presentation may be accessed under
the Investors & Media section of Olema’s website
(www.olema.com) and will be archived for 14
days.
About Olema Oncology Olema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development, and commercialization of targeted therapies for
women’s cancers. Olema’s lead product candidate, OP-1250, is an
orally available small molecule with combined activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated as a single
agent in an ongoing Phase 1/2 clinical trial in patients with
recurrent, locally advanced or metastatic ER-positive (ER+), human
epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Olema is headquartered in San Francisco and has operations in
Cambridge, Massachusetts.
Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Aug 2023 to Aug 2024